Search is Powered by Google
Pharma Industry / Biotech Industry News

Developers Finding Success Of Injectable Drugs Dependent On Numerous Factors -Analysis Trends And Prospects For Six Key Drug Classes

Main Category: Pharma Industry / Biotech Industry
Also Included In: Medical Devices
Article Date: 08 May 2008 - 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:1 star

1 (1 votes)

Health Professional:2 stars

2 (1 votes)

Article Opinions: 0 posts

Technology has a way of providing benefits that create complexities, a lesson that drug developers and their supply chain partners are learning to deal with. Historically, the success of new drugs has focused on tolerability, safety, and pharmacokinetics. The challenges of biologically-derived drugs have added new requirements to successful drug development. Because of their far-reaching physiological effects, environmental instability and limited half-lives, recombinant drugs are pushing drug technology in a number of areas including formulation science, packaging, and delivery.

The formulation of biologics is testing the limits of drug development. The use of polymers to stabilize protein and peptide drugs is growing, and advances in drying and reconstitution are providing new options. For drugs designed to be administered by the patient, therapy-specific packaging is improving compliance and treatment outcomes. In the area of delivery, reusable injection devices designed to accept prefilled syringes or drug cartridges is improving ease-of-use and increasing the alternative device share of the growing self-injection market.

In terms of market value, most of the current demand in injectable drugs can be traced to six drug classes. For companies competing in these drug sectors, the stakes are significant and the cost of failure prohibitive. These drugs had total world sales of about $40 billion in 2007. As biological drugs currently in late-stage development become commercialized, the importance of injectable drugs to company business performance will grow considerably.

These findings are contained in a comprehensive report, researched and prepared by Greystone Associates. More information is available at http://www.greystoneassociates.org.

About Greystone

Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.

Greystone Associates




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Sanofi Aventis Invests 100 Million Euros In New Facility In Mexico To Produce Seasonaland Pandemic Influenza Vaccine
19 Mar 2009
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY), announced the signing of an agreement with the Mexican authorities to build a 100 million euro facility to manufacture influenza vaccine in Mexico...


Running Tips
Running Tips

Beginning a running program may seem daunting at first, but it is a gradual process. Fitness expert Jonathan Cane provides tips for beginning runners.

more videos are available in our health videos section.